Pediatric Allergic Contact Dermatitis: Screening, Allergens, and Why Diagnosis Changes Everything

Allergic contact dermatitis in children is more common than many clinicians may realize and missing the diagnosis carries real consequences for young patients, Jeff Yu, MD, told Dermatology Times at the 2026 American Academy of Dermatology Annual Meeting. Yu’s session covered how to diagnose and screen for the condition, how to determine which children should be screened, and which allergens are most relevant today.

According to Yu, who is chair of dermatology at Virginia Commonwealth University in Richmond, Virginia, the clinical landscape is shifting. "The tides have been changing a little bit where we're really starting to recognize that allergic contact dermatitis can occur in children more and more," he said, noting that more clinicians are patch testing pediatric patients and thinking critically about allergen exposure.

Who Should Be Screened

Yu's core message for practicing dermatologists is to keep the diagnosis on the radar, particularly for patients whose presentation does not quite fit. "We still need to keep up the good work in terms of making sure that we're screening kids who have maybe a little bit of atypical eczema to think about, maybe this could be allergic contact dermatitis," he told Dermatology Times. The follow-up questions, he said, are straightforward: what are they coming in contact with, and how do we best avoid it?

The stakes of missing the diagnosis are significant, Yu said, as it can lead to inappropriate management strategies. "A lot of times people assume that maybe this is atopic dermatitis, maybe this is a form of eczema," he said. "And oftentimes these kids unnecessarily go on either long-term topical steroid use or some sort of a systemic therapy that maybe they don't need to be on in the first place."

Treatment and Allergen Avoidance

When it comes to management, Yu was clear about the only path to definitive resolution—avoidance of the allergen. That said, he outlined a practical tiered approach to symptom control. For mild cases where the allergen has not been identified or cannot be avoided, topical therapies approved for atopic dermatitis (eg, including topical steroids, PDE4 inhibitors, and JAK inhibitors) can be effective. For severe, systemic, or refractory cases, he said biologics and oral JAK inhibitors are reasonable options.

Yu used lanolin as an example of how unrecognized allergen exposure can perpetuate disease. Lanolin is a common ingredient in moisturizers frequently recommended for children with atopic dermatitis, he explained, and if the child is allergic and keeps using it, the rash persists. "You're going to think maybe they just have really bad AD," he said. "But then once you have that diagnosis, you're probably going to go on some sort of a systemic therapy."

What Remains Unknown

Yu also addressed gaps in the field's understanding of contact allergy over time. The natural history of contact allergens across a patient's lifespan remains poorly characterized, he reported, in part because once an allergen is identified, clinicians guide patients to avoid it rather than continuing to track it. His working assumption is that contact allergies are likely stable over time, particularly with ongoing exposure, but he acknowledged the evidence base for this is limited.

His research program at VCU is actively focused on improving diagnostic approaches for contact dermatitis, alongside clinical trial work spanning conditions including vitiligo, hidradenitis suppurativa, and lichen planopilaris. "Anything that we can bring to patients can do a significant amount of good," Yu told Dermatology Times.

To learn more about treatment challenges in pediatric population, consider attending our Revolutionizing Atopic Dermatitis Conference this summer.

Reference
1. Yu J. Considerations in Allergic Contact Dermatitis in Children. Presented at the 2026 American Academy of Dermatology Annual Meeting; March 27-31, 2026; Denver, Colorado.